Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for predicting and enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, and method for evaluating cancer grade

A PD-L1 and PD-1 technology, applied in chemical instruments and methods, anti-animal/human immunoglobulins, antibodies, etc., can solve problems such as unclear correlation and difficulty in determining the intensity of PD-L1 expression

Pending Publication Date: 2020-03-31
J PHARMA +2
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in recent years, the effective rate of anti-PD-1 monoclonal antibody drugs or anti-PD-L1 monoclonal antibody drugs is not significantly correlated with the expression intensity of PD-L1 protein in cancer tissues of patients, and it is difficult to say whether PD-L1 The situation where the measurement of expression intensity plays a role as a so-called companion diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting and enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, and method for evaluating cancer grade
  • Method for predicting and enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, and method for evaluating cancer grade
  • Method for predicting and enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, and method for evaluating cancer grade

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0088] (Staining Example 1)

[0089] Cancer tissues were collected from 3 cancer patients, and single sections were double-stained with anti-LAT1 antibody and anti-PD-L1 antibody, and the results are shown in Figure 1 to Figure 3 .

[0090] figure 1 This is an example of the staining result of lung cancer tissue (magnification 400 times). The left side of the upper row shows a photograph when LAT1 is stained with a green pigment, the right side of the upper row shows a photograph when PD-L1 is stained with a red pigment, and the lower row shows a photograph obtained by superimposing the two. In this lung cancer tissue, PD-L1 staining was predominant.

[0091] figure 2 This is an example of the staining results of breast cancer tissue (magnification 400 times). The left side of the upper row shows a photograph when LAT1 is stained with a green dye, the right side of the upper row shows a photograph when PD-L1 is stained with a red dye, and the lower row shows a photogra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a method for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy and a method for evaluating the grade of a cancer that arebased on a novel biomarker. This method for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy on a subject includes a step for measuring the LAT1 expression level in a sample collected from the cancerous tissue of the subject, and a step for predicting the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy on the subject on the basis of the LAT1 expression level. The method for evaluating the grade of a cancer in a subject includes a step for using anti-LAT1 antibodies and anti-PD-L1 antibodies to stain a sample collected from the cancerous tissue of the subject, and a step for evaluating the grade of the cancer in the subject on the basis of the presence or absence of LAT1-positive and PD-L1-positive sites.

Description

technical field [0001] The present invention relates to a method for predicting the effectiveness of anti-PD-1 antibody or anti-PD-L1 antibody therapy, a method for evaluating the malignancy of cancer, and a method for improving the effectiveness of anti-PD-1 antibody or anti-PD-L1 antibody therapy. Background technique [0002] Developed drugs targeting PD-1 (Programmed cell death 1) / PD-L1 (Programmed cell death ligand-1) as immune checkpoint inhibitors . For example, as anti-PD-1 monoclonal antibodies, nivolumab and pembrolizumab were developed, and as anti-PD-L1 monoclonal antibodies, atezolizumab, avelumab, and durvalumab were developed. In addition, as a method of predicting the effectiveness of anti-PD-1 antibody therapy, a method of investigating PD-L1 expression in cancer cells of patients has been developed. [0003] The expression of PD-L1 is inversely correlated with prognosis in various cancers (renal cancer, esophageal cancer, gastric cancer, urothelial cancer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/48G01N33/53G01N33/574C07K16/28
CPCC07K16/28G01N33/48G01N33/53G01N33/574G01N33/68G01N33/57492G01N33/57423G01N2333/70532G01N2333/70596G01N2800/52A61K31/423A61K2300/00G01N33/6854G01N33/6893G01N33/57419G01N33/57438A61K31/42A61P35/00G01N2800/56A61K2039/505C07K16/2818C07K16/2827
Inventor 远藤仁石原豪史解良恭一金井好克
Owner J PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com